GB1509707A - Immunological compounds - Google Patents

Immunological compounds

Info

Publication number
GB1509707A
GB1509707A GB41037/74A GB4103774A GB1509707A GB 1509707 A GB1509707 A GB 1509707A GB 41037/74 A GB41037/74 A GB 41037/74A GB 4103774 A GB4103774 A GB 4103774A GB 1509707 A GB1509707 A GB 1509707A
Authority
GB
United Kingdom
Prior art keywords
tumor
chloroethyl
cytotoxic
sept
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB41037/74A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle and Co Ltd
GD Searle LLC
Original Assignee
GD Searle and Co Ltd
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle and Co Ltd, GD Searle LLC filed Critical GD Searle and Co Ltd
Priority to GB41037/74A priority Critical patent/GB1509707A/en
Priority to JP50113541A priority patent/JPS5161640A/ja
Priority to NL7511089A priority patent/NL7511089A/xx
Priority to FR7528837A priority patent/FR2285145A1/fr
Priority to SE7510505A priority patent/SE7510505L/xx
Priority to DK422475AA priority patent/DK141773B/da
Priority to DE19752541931 priority patent/DE2541931A1/de
Publication of GB1509707A publication Critical patent/GB1509707A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Metal Rolling (AREA)
  • Peptides Or Proteins (AREA)
GB41037/74A 1974-09-20 1974-09-20 Immunological compounds Expired GB1509707A (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GB41037/74A GB1509707A (en) 1974-09-20 1974-09-20 Immunological compounds
JP50113541A JPS5161640A (en) 1974-09-20 1975-09-19 Koshuyozaino seizoho
NL7511089A NL7511089A (nl) 1974-09-20 1975-09-19 Immunologische verbindingen.
FR7528837A FR2285145A1 (fr) 1974-09-20 1975-09-19 Composes immunologiques et procede de leur preparation
SE7510505A SE7510505L (sv) 1974-09-20 1975-09-19 Forfarande for framstellning av ett antitumormedel
DK422475AA DK141773B (da) 1974-09-20 1975-09-19 Fremgangsmåde til fremstilling af et antitumormiddel.
DE19752541931 DE2541931A1 (de) 1974-09-20 1975-09-19 Immunologische verbindungen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB41037/74A GB1509707A (en) 1974-09-20 1974-09-20 Immunological compounds

Publications (1)

Publication Number Publication Date
GB1509707A true GB1509707A (en) 1978-05-04

Family

ID=10417824

Family Applications (1)

Application Number Title Priority Date Filing Date
GB41037/74A Expired GB1509707A (en) 1974-09-20 1974-09-20 Immunological compounds

Country Status (7)

Country Link
JP (1) JPS5161640A (cg-RX-API-DMAC7.html)
DE (1) DE2541931A1 (cg-RX-API-DMAC7.html)
DK (1) DK141773B (cg-RX-API-DMAC7.html)
FR (1) FR2285145A1 (cg-RX-API-DMAC7.html)
GB (1) GB1509707A (cg-RX-API-DMAC7.html)
NL (1) NL7511089A (cg-RX-API-DMAC7.html)
SE (1) SE7510505L (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401592A (en) 1978-12-29 1983-08-30 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
GB2148299A (en) * 1983-09-01 1985-05-30 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
DE3513572A1 (de) * 1985-04-16 1986-10-16 Karl Prof. Dr.med. 7302 Ostfildern Theurer Herstellung von praeparaten zur spezifischen beeinflussung der humoralen und zellulaeren immunreaktion
US5773435A (en) * 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067971A (en) * 1976-05-13 1978-01-10 The Procter & Gamble Company Therapeutic composition
JPS54132503A (en) * 1978-04-07 1979-10-15 Kayaku Antibiotic Research Co Immune globulin combined neocarcinostatin
JPS5592325A (en) * 1978-12-29 1980-07-12 Kureha Chem Ind Co Ltd Antitumor agent and its preparation
JPS5665829A (en) * 1979-11-02 1981-06-03 Kureha Chem Ind Co Ltd Antitumor agent
JPS5665828A (en) * 1979-11-02 1981-06-03 Kureha Chem Ind Co Ltd Antitumor agent
DE3167679D1 (en) * 1980-03-31 1985-01-24 Inst Int Pathologie Cellulaire Pharmaceutical forms, their preparation and compositions containing the same
JPS58118520A (ja) * 1982-01-09 1983-07-14 Hidematsu Hirai 抗腫瘍性蛋白複合体およびその製造法
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
JPS62228025A (ja) * 1985-12-27 1987-10-06 Teijin Ltd 抗体複合体の製造方法
WO1988007553A1 (fr) * 1987-03-26 1988-10-06 Teijin Limited Procede de preparation d'un complexe d'anticorps
AU649275B2 (en) * 1990-11-06 1994-05-19 Bristol-Myers Squibb Company Prodrugs for beta-lactamase and uses thereof
DE4122210C2 (de) * 1991-07-04 1999-04-01 Deutsches Krebsforsch Konjugate aus tumoraktiver Verbindung und Serumalbumin sowie Verfahren zu deren Herstellung und ihre Verwendung

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401592A (en) 1978-12-29 1983-08-30 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
GB2148299A (en) * 1983-09-01 1985-05-30 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
DE3513572A1 (de) * 1985-04-16 1986-10-16 Karl Prof. Dr.med. 7302 Ostfildern Theurer Herstellung von praeparaten zur spezifischen beeinflussung der humoralen und zellulaeren immunreaktion
US5773435A (en) * 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof

Also Published As

Publication number Publication date
DK141773B (da) 1980-06-16
DK141773C (cg-RX-API-DMAC7.html) 1980-11-03
FR2285145B1 (cg-RX-API-DMAC7.html) 1980-05-30
NL7511089A (nl) 1976-03-23
JPS5161640A (en) 1976-05-28
FR2285145A1 (fr) 1976-04-16
DK422475A (cg-RX-API-DMAC7.html) 1976-03-21
DE2541931A1 (de) 1976-04-01
SE7510505L (sv) 1976-03-22

Similar Documents

Publication Publication Date Title
GB1509707A (en) Immunological compounds
Jeffrey et al. Axoplasmic transport
ATE155818T1 (de) Nicht glycosylierter anti-cd3-igg-antikörper
DK191985D0 (da) Terapeutiske antistofpraeparater med forlaenget serumhalveringstid
SG96535A1 (en) Pharmaceutical composition for the treatment or prevention of a malignant tumor
EP0420913A4 (en) Heterofunctional cellular immunological reagents, vaccines containing same and methods for the use of same
FI950062A0 (fi) Proteiinien foroaktivaatio konjugaatiotarkoituksia varten
NO965239L (no) Monoklonalt antistoff mot CD44v6
ATE296312T1 (de) Metalkomplexbildner
DE3485289D1 (de) Monoklonalantikoerperabfassung fuer diagnostischen gebrauch.
ATE87368T1 (de) Monoklonale antikoerper gegen nicht reduzierte, nicht enzymatisch glykolysierte proteine.
CA2149770A1 (en) Detection of hypoxia
SE8103198L (sv) Forfarande for framstellning av antikroppar
Nandedkar et al. Mn++ binding by plasma proteins
GB1492252A (en) Determination of antipyrine
CA2036814A1 (en) Monoclonal antibodies against tumor-associated antigens, a process for the preparation thereof and the use thereof
AU8100291A (en) Pancreas-elastasis-1-specific antibody, a process for obtaining it and a test kit containing such antibodies
KR850001531A (ko) 인체 내부 백혈소-2(tcgf)와 인체면역글로부린의 빛 入연쇄에 대한 공통 구조를 인지하는 단일 영양 항체 및 단일 영양 항체를 생성하는 하이브리도마 세포계통
GB1136039A (en) Improvements relating to immunosuppressive agents
GB1411553A (en) Motor vehicle exhaust system and mountings therefor
GB1334884A (en) Aminoalcohols and their conversion to aminoketones
CA2038030A1 (en) Synthetic peptides which contain sequences from factor viia, and the use thereof
GB1463908A (en) 1-dimethylamino-methyl-6-substituted-4h-s-triazolo-4,3-a- 1,4-benzodiazepine
AU7145087A (en) Tumor-associated antigens (mol wt 160,000-170,000; 44,000-46,000; 29,000-35,000)
VTYURINA Moscow BIOLOGICHESKIYE MEMBRANY in Russian Vol 1, No 11, Nov &h (manuscript received 10 May 8k) pp II61-II70 VTYURINA, I. Yu., KURYATOV, AB, KISELEV, AV, KHOROSHILOVA, NI OVECHKINA, GV, ABDULAYEV, NG, TSETLIN, VI and VASILOV, RG,'Institute of Bioorganic Chemistry imeni MM Shemyakin, USSR Academy'of

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PCNP Patent ceased through non-payment of renewal fee